Neurologic Imaging

What Imaging Is Best for Monitoring Alzheimer’s Patients on Anti-Amyloid Therapy?

·
What Imaging Is Best for Monitoring Alzheimer's Patients on Anti-Amyloid Therapy?

It’s a busy afternoon in your neurology clinic. You’re seeing a 74-year-old patient with established Alzheimer disease who started on an anti-amyloid monoclonal antibody three months ago. Today’s visit is for routine follow-up; the patient is clinically stable, but the treatment protocol calls for surveillance imaging to monitor for potential side effects before the next infusion. You need to order the correct study to screen for specific, known complications of this therapy class. What is the most appropriate and effective imaging modality for this post-treatment monitoring scenario? The American College of Radiology (ACR) rates MRI head without IV contrast as Usually appropriate for this specific clinical need.

Who Fits This Clinical Scenario for Post-Treatment Alzheimer’s Imaging?

This guidance applies to a very specific patient population: adults with a confirmed diagnosis of Alzheimer disease who are currently undergoing therapy with an anti-amyloid monoclonal antibody (e.g., lecanemab, aducanumab, donanemab). The imaging is performed for routine, scheduled monitoring as specified by treatment protocols, or to evaluate new, non-acute symptoms that could be attributable to therapy side effects.

This workflow is distinct from several related clinical situations. It is crucial to differentiate this scenario from:

  • Pre-treatment evaluation: A patient with known Alzheimer disease who is being considered for anti-amyloid therapy requires baseline imaging. This falls under a different ACR variant, “Known Alzheimer disease considering therapy with anti-amyloid monoclonal antibodies. Pretreatment imaging.” The goal there is to establish a baseline, particularly for pre-existing microhemorrhages, which can influence treatment decisions.
  • Initial dementia workup: A patient presenting with cognitive decline but without a confirmed diagnosis of Alzheimer disease requires a different diagnostic approach. They would fit scenarios like “Suspect Alzheimer disease with typical clinical presentation” or other initial workup variants.
  • Acute, severe neurologic deficit: If a patient on this therapy develops sudden, severe, or stroke-like symptoms, the immediate workup may prioritize an acute stroke protocol over a standard monitoring scan, although the underlying cause may still be a treatment complication.

This article focuses exclusively on the post-treatment monitoring phase for patients already on therapy.

What Are You Looking For? The Differential in Post-Treatment Monitoring

In this context, the imaging “workup” is not for a new diagnosis but for detecting specific, anticipated treatment-related complications. The primary targets are known as Amyloid-Related Imaging Abnormalities, or ARIA.

Amyloid-Related Imaging Abnormalities-Edema/Effusion (ARIA-E)
This is one of the most common and critical findings to monitor. ARIA-E represents vasogenic edema (swelling in the brain parenchyma) or sulcal effusions (fluid collecting in the grooves on the brain’s surface). It is thought to result from increased vascular permeability as amyloid plaques are cleared from vessel walls. While often asymptomatic and detected only on surveillance scans, ARIA-E can cause symptoms like headache, confusion, dizziness, or focal neurologic deficits. Its detection is a key decision point for continuing, pausing, or stopping therapy.

Amyloid-Related Imaging Abnormalities-Hemorrhage (ARIA-H)
This category includes new or enlarging microhemorrhages (tiny bleeds) and superficial siderosis (iron deposition on the brain surface from prior bleeding). Patients with underlying cerebral amyloid angiopathy are at higher risk. Like ARIA-E, ARIA-H is often asymptomatic. However, a significant increase in the number or size of microhemorrhages, or the development of a larger intracranial hemorrhage, is a major safety concern that directly impacts treatment management.

New Ischemic or Hemorrhagic Stroke
Beyond the specific definitions of ARIA, patients remain at risk for other cerebrovascular events. The ordered imaging study must be capable of identifying and characterizing new territory infarcts or larger parenchymal or subarachnoid hemorrhages that are distinct from the typical ARIA findings. Differentiating a symptomatic ARIA event from a coincidental stroke is a crucial clinical task.

Why Is MRI Head without IV Contrast the Recommended Study for Monitoring ARIA?

The ACR designates MRI head without IV contrast as Usually appropriate because it provides the highest sensitivity for detecting both forms of ARIA without exposing the patient to ionizing radiation or intravenous contrast agents. The specific sequences within a non-contrast MRI protocol are perfectly suited for this surveillance task.

The rationale for this choice is rooted in sequence-specific strengths:

  • FLAIR (Fluid-Attenuated Inversion Recovery): This sequence is exceptionally sensitive for detecting the vasogenic edema and sulcal effusions of ARIA-E. These abnormalities appear as bright (hyperintense) signals, making them conspicuous against the suppressed signal from normal cerebrospinal fluid.
  • SWI (Susceptibility-Weighted Imaging) or GRE (Gradient-Recalled Echo): These sequences are essential for detecting ARIA-H. They are highly sensitive to the magnetic susceptibility effects of blood breakdown products (hemosiderin), causing microhemorrhages and areas of siderosis to appear as distinct, dark (hypointense) foci.
  • DWI (Diffusion-Weighted Imaging): This sequence is critical for identifying acute or subacute ischemia, helping to differentiate a new stroke from edema related to ARIA-E.

This combination of sequences within a single, non-contrast MRI examination allows for comprehensive screening for the most important treatment-related complications.

In contrast, other modalities are rated lower for this specific scenario. A non-contrast CT head is Usually not appropriate because it has very poor sensitivity for both ARIA-E and ARIA-H, especially when the findings are subtle. It may miss clinically significant changes. Similarly, adding IV contrast (MRI or CT) is Usually not appropriate as it does not improve the detection of ARIA and adds unnecessary risk and cost. Functional studies like Amyloid PET/CT, while used for diagnosis, are not the correct tool for monitoring these structural complications of therapy and are rated May be appropriate (Disagreement), reflecting their limited role in this specific surveillance context.

What’s Next After MRI Head without IV Contrast? Downstream Workflow

The radiologist’s report is a critical input into the clinical decision-making process for managing anti-amyloid therapy. The next steps depend directly on the imaging findings, interpreted in the context of the patient’s clinical status.

  • If the study is negative for ARIA: If the patient is asymptomatic and the MRI shows no new or worsening ARIA-E or ARIA-H, treatment can typically continue as planned per the medication’s prescribing information. The patient continues with the scheduled clinical and imaging surveillance.
  • If the study is positive for asymptomatic ARIA: The detection of new, asymptomatic ARIA-E or ARIA-H requires careful consideration. Management guidelines, which vary slightly by drug, often recommend increased surveillance with more frequent MRI scans. Depending on the severity (e.g., number of new microhemorrhages, extent of edema), a temporary suspension of treatment may be recommended until the abnormalities resolve or stabilize.
  • If the study is positive for symptomatic ARIA: If the patient has symptoms attributable to new ARIA findings on MRI, treatment is almost always suspended. In severe cases, permanent discontinuation of the therapy may be necessary. Management may also include short-term corticosteroid therapy for severe symptomatic ARIA-E.
  • If the findings are indeterminate: In rare cases where the findings are ambiguous (e.g., difficult to distinguish from a small stroke or other pathology), a follow-up MRI in a shorter interval (e.g., 4-6 weeks) may be warranted to assess for evolution. Consultation with a neuroradiologist can be invaluable in these situations.

Pitfalls to Avoid (and When to Get Help)

When monitoring patients on anti-amyloid therapies, several common pitfalls can compromise patient safety and effective management.

First, avoid ordering a CT scan as a substitute for MRI for routine surveillance. CT lacks the sensitivity to detect the subtle edema of ARIA-E and the microhemorrhages of ARIA-H, potentially leading to a false sense of security. Second, ensure the MRI protocol specifically includes FLAIR and a susceptibility-sensitive sequence (SWI or GRE); a “standard” brain MRI protocol at some centers might omit these, rendering the scan inadequate for ARIA assessment. Third, do not dismiss mild, new symptoms like headache or dizziness without a low threshold for imaging, as these can be the first sign of clinically significant ARIA.

If a patient presents with severe or rapidly progressing neurologic symptoms, or if imaging reveals a large hemorrhage or extensive edema, this constitutes a neurologic emergency. Escalate care immediately, involving neurology and potentially neurocritical care specialists.

Related ACR Topics and Tools

This article covers one specific scenario in depth. For a comprehensive overview of imaging for all dementia-related presentations, from initial workup to differential diagnosis, please see our parent guide.

Frequently Asked Questions

How often should MRI monitoring be performed for patients on anti-amyloid therapy?

The frequency of surveillance MRI is dictated by the specific drug’s prescribing information and clinical trial protocols. Typically, MRIs are recommended before the 5th, 7th, and 14th infusions, but this schedule can be adjusted based on clinical symptoms or prior imaging findings. Always refer to the most current FDA-approved label for the specific agent being used.

Is a contrast-enhanced MRI ever needed in this scenario?

For the specific purpose of monitoring for ARIA, intravenous contrast is not necessary and is rated ‘Usually not appropriate’ by the ACR. The key findings of edema (ARIA-E) and microhemorrhage (ARIA-H) are best visualized on non-contrast FLAIR and SWI/GRE sequences, respectively. Contrast would only be considered if there is a separate clinical suspicion for a different pathology, such as a brain tumor or infection.

What is the difference between pre-treatment and post-treatment imaging goals?

Pre-treatment imaging establishes a baseline. Its primary purpose is to identify pre-existing conditions, especially the burden of cerebral microhemorrhages, which may place a patient at higher risk for ARIA-H and could influence the decision to start therapy. Post-treatment imaging, the focus of this article, is for surveillance to detect new or worsening ARIA as a direct complication of the therapy.

Can Amyloid PET imaging be used to monitor for ARIA?

No, Amyloid PET is a molecular imaging technique designed to detect the presence and density of amyloid plaques in the brain. It is a diagnostic tool, not a tool for monitoring the structural complications of therapy like edema and hemorrhage. While it is rated ‘May be appropriate (Disagreement)’ by the ACR for this scenario, its use is not for ARIA detection but for other, less common clinical questions. MRI is the correct modality for ARIA surveillance.

If a patient has an MRI-incompatible device, what is the alternative for ARIA monitoring?

This is a challenging clinical situation, as non-contrast CT is significantly less sensitive for ARIA. If a patient with an MRI-incompatible device is being considered for this therapy, a thorough risk-benefit discussion is essential, acknowledging the limitations of surveillance. In some cases, therapy may be contraindicated. If the patient is already on therapy, a non-contrast CT can be performed, but the clinician must be aware that it may fail to detect mild or even moderate ARIA, and clinical monitoring becomes even more critical.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026